stockrowBausch + Lomb Corporation
BLCO Healthcare Medical Instruments & Supplies
Bausch + Lomb Corporation’s revenue for fiscal 2025 (year ended December 2025) was $5.1 billion, up 6.47% from fiscal 2024.
- Revenue
- +7.34%
- EPS
- +222.4%
- Free cash flow
- +182.5%
- Total debt
- +2.93%
Quarter to September 2026, against a year earlier
Follow BLCO
Alert me
Bausch + Lomb Corporation (BLCO) Return on equity
Bausch + Lomb Corporation's return on equity over the twelve months to 30 September 2026 was −1.71%, up 3.8 percentage points from fiscal 2025 (−5.51%). Over the past ten years it has ranged from −5.51% (fiscal 2025) to 1.88% (fiscal 2021) — the current reading is the lowest in ten years. That is below the Medical Instruments & Supplies industry median of 0.00% and above the Healthcare sector median of −26.3%.
Return on equity, annual
Embed this chart
Annual newest first
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2025 | −5.51% | (0.80) |
| FY2024 | −4.71% | (1.00) |
| FY2023 | −3.71% | (3.78) |
| FY2022 | 0.07% | (1.81) |
| FY2021 | 1.88% | 1.88 |
| FY2020 | 0.00% | — |
Against its own ten years
Return on equity against peers
| Company | Return on equity |
|---|---|
| ATR AptarGroup, Inc. compare | 9.86% |
| MMSI Merit Medical Systems, Inc. compare | 9.78% |
| COO The Cooper Companies, Inc. compare | 6.84% |
| AVTR Avantor, Inc. compare | 5.91% |
| MMED MiniMed Group, Inc. compare | 0.00% |
| ALGN Align Technology, Inc. compare | 0.00% |
| RGEN Repligen Corporation compare | −0.57% |
| BLCO Bausch + Lomb Corporation | −1.71% |
| TFX Teleflex Incorporated compare | −28.9% |
| Medical Instruments & Supplies industry median | 0.00% |
| Healthcare sector median | −26.3% |
| Market median | 0.51% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)
More on BLCO
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement